1271 related articles for article (PubMed ID: 31202359)
1. Immunometabolism: A new target for improving cancer immunotherapy.
Guo C; Chen S; Liu W; Ma Y; Li J; Fisher PB; Fang X; Wang XY
Adv Cancer Res; 2019; 143():195-253. PubMed ID: 31202359
[TBL] [Abstract][Full Text] [Related]
2. Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy.
Fan C; Zhang S; Gong Z; Li X; Xiang B; Deng H; Zhou M; Li G; Li Y; Xiong W; Zeng Z; Li X
Sci China Life Sci; 2021 Apr; 64(4):534-547. PubMed ID: 32815067
[TBL] [Abstract][Full Text] [Related]
3. CD147‑mediated reprogrammed glycolytic metabolism potentially induces immune escape in the tumor microenvironment (Review).
Li X; Xu W
Oncol Rep; 2019 May; 41(5):2945-2956. PubMed ID: 30864716
[TBL] [Abstract][Full Text] [Related]
4. Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy.
Yin Z; Bai L; Li W; Zeng T; Tian H; Cui J
J Exp Clin Cancer Res; 2019 Sep; 38(1):403. PubMed ID: 31519198
[TBL] [Abstract][Full Text] [Related]
5. Immune-mediated anti-tumor effects of metformin; targeting metabolic reprogramming of T cells as a new possible mechanism for anti-cancer effects of metformin.
Bahrambeigi S; Shafiei-Irannejad V
Biochem Pharmacol; 2020 Apr; 174():113787. PubMed ID: 31884044
[TBL] [Abstract][Full Text] [Related]
6. T-cell immunometabolism against cancer.
Jiang S; Yan W
Cancer Lett; 2016 Nov; 382(2):255-258. PubMed ID: 27664755
[TBL] [Abstract][Full Text] [Related]
7. Harnessing Metabolic Reprogramming to Improve Cancer Immunotherapy.
Yan L; Tan Y; Chen G; Fan J; Zhang J
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638609
[TBL] [Abstract][Full Text] [Related]
8. TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy.
Huang L; Xu H; Peng G
Cell Mol Immunol; 2018 May; 15(5):428-437. PubMed ID: 29553135
[TBL] [Abstract][Full Text] [Related]
9. Metabolic Checkpoints: Novel Avenues for Immunotherapy of Cancer.
Shevchenko I; Bazhin AV
Front Immunol; 2018; 9():1816. PubMed ID: 30131808
[TBL] [Abstract][Full Text] [Related]
10. Dysfunctional T cell metabolism in the tumor microenvironment.
Beckermann KE; Dudzinski SO; Rathmell JC
Cytokine Growth Factor Rev; 2017 Jun; 35():7-14. PubMed ID: 28456467
[TBL] [Abstract][Full Text] [Related]
11. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
Wang H; Franco F; Ho PC
Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935
[TBL] [Abstract][Full Text] [Related]
12. Innate and Adaptive Immune Cell Metabolism in Tumor Microenvironment.
Wu D
Adv Exp Med Biol; 2017; 1011():211-223. PubMed ID: 28875492
[TBL] [Abstract][Full Text] [Related]
13. Metabolic reprogramming in the tumour microenvironment: a hallmark shared by cancer cells and T lymphocytes.
Allison KE; Coomber BL; Bridle BW
Immunology; 2017 Oct; 152(2):175-184. PubMed ID: 28621843
[TBL] [Abstract][Full Text] [Related]
14. Linking tumor glycolysis and immune evasion in cancer: Emerging concepts and therapeutic opportunities.
Ganapathy-Kanniappan S
Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):212-220. PubMed ID: 28400131
[TBL] [Abstract][Full Text] [Related]
15. Emerging concepts of T cell metabolism as a target of immunotherapy.
Chang CH; Pearce EL
Nat Immunol; 2016 Apr; 17(4):364-8. PubMed ID: 27002844
[TBL] [Abstract][Full Text] [Related]
16. Immunometabolic rewiring in tumorigenesis and anti-tumor immunotherapy.
Lian X; Yang K; Li R; Li M; Zuo J; Zheng B; Wang W; Wang P; Zhou S
Mol Cancer; 2022 Jan; 21(1):27. PubMed ID: 35062950
[TBL] [Abstract][Full Text] [Related]
17. Obesity induced T cell dysfunction and implications for cancer immunotherapy.
Aguilar EG; Murphy WJ
Curr Opin Immunol; 2018 Apr; 51():181-186. PubMed ID: 29655021
[TBL] [Abstract][Full Text] [Related]
18. Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy.
Rivadeneira DB; Delgoffe GM
Clin Cancer Res; 2018 Jun; 24(11):2473-2481. PubMed ID: 29386217
[TBL] [Abstract][Full Text] [Related]
19. The cancer metabolic reprogramming and immune response.
Xia L; Oyang L; Lin J; Tan S; Han Y; Wu N; Yi P; Tang L; Pan Q; Rao S; Liang J; Tang Y; Su M; Luo X; Yang Y; Shi Y; Wang H; Zhou Y; Liao Q
Mol Cancer; 2021 Feb; 20(1):28. PubMed ID: 33546704
[TBL] [Abstract][Full Text] [Related]
20. Targeting SLC1A5 and SLC3A2/SLC7A5 as a Potential Strategy to Strengthen Anti-Tumor Immunity in the Tumor Microenvironment.
Nachef M; Ali AK; Almutairi SM; Lee SH
Front Immunol; 2021; 12():624324. PubMed ID: 33953707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
